Company intelligence / Profile preview

Mologen AG

Berlin, Berlin, Germanymologen.bio ↗

Ownership: Private
Employees: ~12
Development stage: Phase 2

Overview

Mologen had a Phase III study for Lefitolimod in metastatic colorectal cancer, Phase II trial for small-cell lung cancer, and Phase Ib/IIa study for HIV treatment. They also had a Phase I combination study with checkpoint inhibitor Yervoy for advanced solid tumors.

Therapeutic areas: OncologyInfectious Diseases
Modalities: DNA immunomodulatorCell-based therapiesDNA vaccinesImmunotherapies
Industry: Biotech

Drug pipeline

6 assets

lefitolimod

5 more assets in the full pipeline.

Request access →

Partnerships

Aarhus University Hospital in DenmarkMD Anderson Cancer Center at the University of Texas

Beyond the preview

Go deeper on Mologen AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mologen AG.

Explore the full profile